SIMCERE PHARMAC. GRP LTD risk profile
34 Normal where most of the sector sits
Measured 1 September 2026 from S2P's filed statements. Recomputed nightly.
34 (Normal), driven by Market expectation at 56, over 5 weighted categories on the MANUFACTURER profile.
What is measured
| Mechanism | Reading | Band | Direction | Driver |
|---|---|---|---|---|
| Market expectation | 56 | Elevated | Stable | Drawdown from the 52-week high — 24.7% |
| Operating pressure | 27 | Normal | Worsening | Costs outgrowing revenue — -2.0 percentage points |
| Cash conversion | 27 | Normal | Easing | Capital spending against operating cash — 0.43x |
| Leverage and coverage | 6 | Contained | Stable | Current ratio — 2.21x |
| Competitive position | 43 | Elevated | Stable | Revenue-growth gap against peers — -10.2 percentage points |
| Concentration | Reads identified supplier spend, customers above the 10% disclosure threshold and revenue by region. No reading is stored for this company. | |||
These are descriptive readings of disclosed mechanisms, not investment advice, and not a prediction. A band says where a measured input sits, never what to do about it or what happens next.
Healthcare companies with a risk reading
Lilly(Eli) & Company 17Johnson & Johnson 37Abbvie Inc 46Roche Holding AG 32Merck & Co Inc 26Novartis AG 25Astrazeneca plc 30AMGEN Inc 33Thermo Fisher Scientific Inc 45Novo Nordisk A/S 23Abbott Laboratories 43Gilead Sciences Inc 31
Financials, valuation and price history for SIMCERE PHARMAC. GRP LTD